Building a Successful RMM Strategy: An interview with Michael Loewenstein

[Article Title]

Adoption of rapid microbiological methods has been gradual, but Michael Loewenstein of Q Laboratories says the biggest obstacle is usually not technology or regulation. It is limited internal resources. In this interview he covers the assessments companies should complete before an investment decision, how to structure validation strategies around USP <1223>, what it takes to maintain a validated and compliant system after implementation, and how to narrow the field of RMM technologies and vendors.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.